Table 1.
Demographics | |
---|---|
Median age at presentation (range)—year | 16 (15–18) |
Male sex—no./total no. (%) | 9/11 (82) |
Race—no./total no. (%) | |
White | 10/11 (91) |
Other | 1/11 (9) |
History of asthma | 6/11 (55) |
E-cigarette reported use—no./total no. (%) | |
THC only | 10/11 (91) |
Nicotine only | 8/11 (73) |
Both THC and nicotine | 7/11 (64) |
Other (CBD, cigarette smoking) | 5/11 (45) |
Admission to intensive care unit—no./total no. (%) | 5/11 (45) |
Median length of hospital stay (range)—days | 5 (2–10) |
Symptoms at presentation—no./total no. (%) | |
Respiratory related symptom | 10/11 (91) |
Gastrointestinal related symptom | 11/11 (100) |
Constitutional symptoms | 11/11 (100) |
Initial laboratory results—no./total no. (%) | |
White blood cell count (> 11,000/μL) | 7/11 (64) |
C-reactive protein > 0.9 mg/dL | 6/6 (100) |
Erythrocyte sedimentation rate > 30 mm/h | 8/8 (100) |
Respiratory viral panel PCR—no./total no. (%) | |
Rhinovirus positive | 3/11 (27) |
Negative | 8/11 (73) |
Urine drug screen—no./total no. (%) | |
THC positive | 10/11 (91) |
PCR, polymerase chain reaction; THC, tetrahydrocannabinol; CBD, cannabidiol